Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4482 single- and multiple-dose safety and pharmacokinetic study in healthy Japanese adults
jRCT2031210010Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of molnupiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability after single and multiple oral doses of MK-4482, Plasma N-hydroxycytidine pharmacokinetics after a single oral dose and 1 more. Started Apr 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210010.